default author photo

Suebpong Tanasanvimon

Chulalongkorn University - Division of Medical Oncology

SCHOLARLY PAPERS

2

DOWNLOADS

173

TOTAL CITATIONS

0

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

Immunogenicity and Omicron Neutralization Following a Third COVID-19 Vaccination in Solid Cancer Patients Previously Primed with Two Doses of Chadox1 Vaccine: A Prospective Cohort Study

Number of pages: 32 Posted: 12 Sep 2022
Sutima Luangdilok, Passakorn Wanchaijiraboon, Nussara Pakvisal, Thiti Susiriwatananont, Nicha Zungsontiporn, Virote Sriuranpong, Teerayuth Namkanisorn, Panot Sainamthip, Nungruthai Suntronwong, Preeyaporn Vichaiwattana, Stephen J. Kerr, Nasamon Wanlapakorn, Yong Poovorawan, Nattaya Teeyapun and Suebpong Tanasanvimon
Chulalongkorn University - Department of Biochemistry, Phrapokklao Cancer Center of Excellence, Chulalongkorn University - Division of Medical Oncology, Chulalongkorn University - Division of Medical Oncology, Chulalongkorn University - Division of Medical Oncology, Chulalongkorn University - Division of Medical Oncology, Phrapokklao Cancer Center of Excellence, Chulalongkorn University - Department of Pharmacology, Chulalongkorn University - Center of Excellence in Clinical Virology, Chulalongkorn University - Center of Excellence in Clinical Virology, Chulalongkorn University - Biostatistics Excellence Centre, Chulalongkorn University - Center of Excellence in Clinical Virology, Chulalongkorn University - Center of Excellence in Clinical Virology, Chulalongkorn University - Division of Medical Oncology and Chulalongkorn University - Division of Medical Oncology
Downloads 110 (639,995)

Abstract:

Loading...

COVID-19 vaccine, booster vaccine, third dose vaccine, omicron, ChAdOx1, cancer, immunogenicity

2.

Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac

Number of pages: 27 Posted: 13 Aug 2022
Passakorn Wanchaijiraboon, Panot Sainamthip, Nattaya Teeyapun, Sutima Luangdilok, Yong Poovorawan, Nasamon Wanlapakorn, Piyapoom Pakvisal, Thiti Susiriwatananont, Nicha Zungsontiporn, Suebpong Tanasanvimon, Virote Sriuranpong and Nussara Pakvisal
Phrapokklao Cancer Center of Excellence, Chulalongkorn University - Department of Pharmacology, Chulalongkorn University - Division of Medical Oncology, Chulalongkorn University - Department of Biochemistry, Chulalongkorn University - Center of Excellence in Clinical Virology, Chulalongkorn University - Center of Excellence in Clinical Virology, Police General Hospital, Chulalongkorn University - Division of Medical Oncology, Chulalongkorn University - Division of Medical Oncology, Chulalongkorn University - Division of Medical Oncology, Chulalongkorn University - Division of Medical Oncology and Chulalongkorn University - Division of Medical Oncology
Downloads 63 (933,353)

Abstract:

Loading...

ChAdOx1, CoronaVac, BNT162b2, mRNA-1273, Booster Covid-19 vaccine, Safety, Cancer patients